HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, has announced a workforce reduction of 40%—or about 41 employees—to reduce its operating expenses.   The layoffs are intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates as well as business development-related activities for these vaccine candidates. ...